Terufumi Kato

19PUBLICATIONS
148CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsPredictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Sep 09, 2026
Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study.

|Aug 26, 2026
AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.

|Jul 15, 2026
Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.

|Jun 02, 2026
Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

|Mar 09, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Jhanelle E Gray, Konstantin Laktionov, Sang-We Kim

|Jun 27, 2025
Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan.

Terufumi Kato, Tatsuya Ogura, Masashi Sato

Pageof 4

Frequent Collaborators

4 joint publications

Yi-Long Wu

3 joint publications

Shoichi Kuyama

3 joint publications

Konstantin Laktionov

3 joint publications

Sang-We Kim